Related Experiment Videos
Meta-analysis: budesonide treatment for collagenous colitis.
B Feyen1, G C Wall, E P Finnerty
1Internal Medicine Resident, Iowa Methodist Medical Center, Des Moines, IA 50309, USA. geoff.wall@drake.edu
Alimentary Pharmacology & Therapeutics
|September 24, 2004
Summary
Budesonide significantly reduces watery diarrhea in collagenous colitis patients. This corticosteroid treatment is effective short-term and generally well-tolerated, offering a viable option for managing this condition.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Collagenous colitis causes chronic watery diarrhea with specific mucosal histology but no endoscopic signs.
- Previous studies on budesonide for collagenous colitis were limited by small sample sizes and low statistical power.
Purpose of the Study:
- To evaluate the treatment efficacy of budesonide in collagenous colitis through a meta-analysis of published trials.
Main Methods:
- A comprehensive literature search was conducted across MEDLINE, EMBASE, and other relevant sources.
- Published English-language reports of budesonide use in collagenous colitis were selected based on prespecified criteria for meta-analysis.
Main Results:
- Three trials were included in the meta-analysis.
- Budesonide demonstrated a significant reduction in stool frequency compared to placebo (OR: 20.1, P < 0.0001).
- The treatment was generally well-tolerated by patients.
Conclusions:
- Budesonide is a clinically effective short-term treatment for collagenous colitis.
- The drug appears to be relatively well-tolerated.
- Budesonide represents a reasonable therapeutic option for clinicians treating patients with collagenous colitis.